Hemostasis activation during sclerotherapy of lower extremity varices.
The influence of compression sclerotherapy upon hemostasis activation was investigated in 41 consecutive patients with lower extremity varices by serial measurement of thrombin-antithrombin III complexes (TAT), D-dimer, fibrinogen and C-reactive protein (CRP). Blood sampling was carried out before operation and on the 7th and 28th post-operative day in patients randomly assigned to either the control group (n = 18), in which high ligation of sapheno-femoral junction and local excision of varices were performed, or the sclerotherapy group (n = 23) in which the comparable surgical intervention and compression sclerotherapy using hypertonic saline were performed simultaneously. In both groups, the TAT, D-dimer and fibrinogen concentrations at day 7 were significantly elevated compared to the value before operation while CRP showed no significant change during the observation period. In the sclerotherapy group, higher incidence of superficial thrombosis was observed and the TAT concentration at day 7 was significantly higher than that in the control group (p < 0.01), and the TAT at day 28 was still significantly elevated compared to the pre-operative level (p < 0.05). However, no relationship between TAT and D-dimer concentrations and the extent of superficial thrombosis was observed. We conclude that compression sclerotherapy for lower extremity varices causes latent activation of coagulation system and can be a risk factor for venous thromboembolism.
Ikeda
M
M
Department of Surgery II, Osaka University Medical School, Japan.
Kambayashi
J
J
Iwamoto
S
S
Shinoki
N
N
Nakamura
T
T
Okahara
K
K
Fujitani
K
K
Shibuya
T
T
Kawasaki
T
T
Monden
M
M
D000990:Antithrombin III / Q000378:metabolism; D001777:Blood Coagulation; D002097:C-Reactive Protein / Q000378:metabolism; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis; D006487:Hemostasis; D006801:Humans; D008297:Male; D008875:Middle Aged; D012501:Saphenous Vein; D015911:Sclerotherapy / Q000009:adverse effects*; D013917:Thrombin / Q000378:metabolism; D013924:Thrombophlebitis / Q000209:etiology; D014648:Varicose Veins / Q000628:therapy*
D005338:Fibrin Fibrinogen Degradation Products; D000990:Antithrombin III; D005340:Fibrinogen; D002097:C-Reactive Protein; D013917:Thrombin